NovaBay® Pharmaceuticals, Inc. (NYSE-AMEX: NBY, http://www.novabaypharma.com), a clinical stage company developing non-antibiotic anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, announced today that Ron Najafi, Ph.D., Chairman and Chief Executive Officer, will present at the Jesup & Lamont 2009 Growth Stock Conference organized by the LifeTech Capital Group on Thursday, July 30, 2009 at 9:30 am EDT. The presentation will be held at The Boca Raton Resort & Club in Boca Raton, Florida.
Dr. Najafi will provide a corporate overview and highlight NovaBay’s clinical progress, business development strategy and product development candidates. His presentation will:
Update investors on NovaBay’s internal clinical programs in hospital-associated infections and respiratory infections.
Provide information on NovaBay’s recent announcements regarding the initiation of a Phase II clinical trial for the use of NovaBay’s lead Aganocide® compound, NVC-422, for viral conjunctivitis, which is being conducted by its partner Alcon (NYSE:ACL).
Review the recently announced partnership with Galderma, the world’s leading dermatology company, for development of acne and impetigo products
Discuss the important collaborative agreement with professors Markus Nagl, M.D. and Waldemar Gottardi, Ph.D. of the Medical University of Innsbruck, Austria, which broadens NovaBay’s intellectual property estate, expands its pre-clinical pipeline and advances the development of NovaBay’s Aganocide® compounds by integrating on-going clinical work at the Medical University with NovaBay’s development programs.
In addition, Dr. Najafi will serve on a key conference panel that will include industry leaders and a former FDA Commissioner to discuss trends in the biotech industry and biotech investing. The panel session will take place at 4:45 pm EDT on Wednesday, July 29, 2009.
About Aganocide® Compounds
The Aganocide® compounds are novel, proprietary, synthetic N-chlorinated antimicrobial molecules specifically developed by NovaBay® to mimic the body’s natural defense against infection. The Aganocide® compounds maintain the biological activities while improving the stability of naturally occurring N-chlorinated antimicrobial molecules. These highly differentiated, first-in-class, small molecule, patented new chemical entities may deliver the same or better efficacy than currently used antibiotics without contributing to the growing rise of antibiotic-resistant bacterial strains. In preclinical testing, the Aganocide® compounds have been shown to be highly effective against bacteria, including its multi-drug resistant strains, viruses and fungi. They also have been demonstrated to be effective against bacteria in biofilms, which render most antibiotics ineffective. Aganocides have a broad therapeutic index while providing a high degree of potency and tolerability as well as dosing versatility and flexibility.
NovaBay® Pharmaceuticals is a mid-stage biopharmaceutical company focused on developing its proprietary and patented Aganocide® compounds, which are novel, synthetic, anti-infective product candidates that are bioequivalent to the active antimicrobial molecules generated within white blood cells to treat and prevent a wide range of infections without causing bacterial resistance. NovaBay® has internal development programs aimed at addressing dermatological, hospital and respiratory infections. The company has a licensing and research collaboration agreement with Alcon, Inc. for use of its Aganocide® compounds to treat eye, ear and sinus infections as well as in contact lens care solutions. NovaBay® has also entered into an agreement with Galderma S.A. to develop and commercialize Aganocides in acne, impetigo and other dermatological indications. For more information on NovaBay, visit: www.novabaypharma.com.
NovaBay Pharmaceuticals Contacts
Thomas J. Paulson
Chief Financial Officer
Contact Thomas Paulson